THE MULTIPLE MYELOMA Research Foundation (MMRF) has announced the launch of MyDRUG, the first platform trial exclusively in multiple myeloma, which aims to investigate targeted treatments for patients with high-risk myeloma. MyDRUG represents the culmination of the MMRF’s Precision Medicine Model, reportedly the only end-to-end model of its type in cancer.
Platform trials enable the rapid testing of actionable agents in patients who might benefit; agents that do not show efficacy in targeted patient populations can be removed from the trial and other new, targeted agents can be inserted quickly and tested. The trial is designed to continue indefinitely, with no limitation on the number of patients enrolled or the number of new agents tested.
The trial will be open to patients with relapsed, refractory multiple myeloma who have:
- Received at least one prior but no more than three prior therapies
- Been exposed to both a proteasome inhibitor and an immuno-modulatory drug
- Had early relapse after initial treatment (defined as at least one of the following): relapse within 3 years after autologous stem cell transplantation (ASCT) on maintenance or 18 months if unmaintained, relapse within 18 months of initial non–ASCT-based therapy.
MyDRUG will be available at 17 Multiple Myeloma Research Consortium sites; to see the full list of sites and arms open, visit www. themmrf.org. Additional information is available on ClinicalTrials. gov (clinicaltrials.gov identifier NCT03732703) or through the MMRF Patient Navigators at 1-866-603-6628.
The MMRF is supported by several pharmaceutical companies in the platform trial. ■
